Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia
Item
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Title
Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia
Subject
Description
The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against coronavirus disease 2019 (Covid-19).
Date
2021-08-19
Type
Citation
Bourguignon, Alex, Donald M. Arnold, Theodore E. Warkentin, James W. Smith, Tania Pannu, Jeffrey M. Shrum, Zainab A. A. Al Maqrashi, Anjali Shroff, Marie-Claude Lessard, Normand Blais, John G. Kelton, and Ishac Nazy. 2021. "Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia." New England Journal of Medicine 385 (8):720-8.
Accessibility
Free online on NEJM.
Was this resource helpful?